Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 225 of 2051 entries
View as:

Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)

Phase: N/A Priority: Normal
NCT ID: NCT02397096 Org: User:
Start: 06/09/15 End: 09/05/23 Due: 09/05/24

MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

Phase: N/A Priority: Normal
NCT ID: NCT00996801 Org: User:
Start: 11/30/09 End: 06/30/11 Due: 06/30/12

Re-examination Study For Varivax (V210-059 AM2)

Phase: N/A Priority: Normal
NCT ID: NCT01062061 Org: User:
Start: 06/30/07 End: 05/31/12 Due: 05/31/13

Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)

Phase: N/A Priority: Normal
NCT ID: NCT03859739 Org: User:
Start: 04/26/19 End: 05/29/20 Due: 05/29/21

A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)

Phase: N/A Priority: Normal
NCT ID: NCT00282763 Org: User:
Start: 12/31/05 End: 08/31/06 Due: 08/31/07

A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)

Phase: N/A Priority: Normal
NCT ID: NCT00836498 Org: User:
Start: 01/31/09 End: 01/31/10 Due: 01/31/11

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Phase: N/A Priority: Normal
NCT ID: NCT03095651 Org: User:
Start: 04/12/17 End: 01/30/18 Due: 01/30/19

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

Phase: N/A Priority: Normal
NCT ID: NCT05893862 Org: User:
Start: 06/26/23 End: 02/22/24 Due: 02/22/25

A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)

Phase: N/A Priority: Normal
NCT ID: NCT00882440 Org: User:
Start: 12/31/90 End: 01/31/92 Due: 01/31/93

Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)

Phase: N/A Priority: Normal
NCT ID: NCT02314923 Org: User:
Start: 12/05/14 End: 06/23/16 Due: 06/23/17

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Phase: N/A Priority: Normal
NCT ID: NCT03898180 Org: User:
Start: 05/06/19 End: 05/20/24 Due: 05/20/25

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)

Phase: N/A Priority: Normal
NCT ID: NCT01390428 Org: User:
Start: 07/28/11 End: 09/12/14 Due: 09/12/15

Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00521924 Org: User:
Start: 06/30/07 End: 04/30/08 Due: 04/30/09

MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)

Phase: N/A Priority: Normal
NCT ID: NCT00076869 Org: User:
Start: 01/31/03 End: 08/31/05 Due: 08/31/06

Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)

Phase: N/A Priority: Normal
NCT ID: NCT00727298 Org: User:
Start: 02/28/06 End: 08/31/11 Due: 08/31/12

Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)

Phase: N/A Priority: Normal
NCT ID: NCT01554176 Org: User:
Start: 05/18/12 End: 09/03/13 Due: 09/03/14

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Phase: N/A Priority: Normal
NCT ID: NCT04924114 Org: User:
Start: 10/14/21 End: 07/15/24 Due: 07/15/25

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

Phase: N/A Priority: Normal
NCT ID: NCT01636947 Org: User:
Start: 12/12/12 End: 08/04/14 Due: 08/04/15

Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)

Phase: N/A Priority: Normal
NCT ID: NCT00394914 Org: User:
Start: 08/31/06 End: 04/30/07 Due: 04/30/08

Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

Phase: N/A Priority: Normal
NCT ID: NCT02137772 Org: User:
Start: 06/06/14 End: 11/21/16 Due: 11/21/17

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

Phase: N/A Priority: Normal
NCT ID: NCT01958671 Org: User:
Start: 10/09/13 End: 07/28/16 Due: 07/28/17

Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)

Phase: N/A Priority: Normal
NCT ID: NCT01097616 Org: User:
Start: 05/05/10 End: 12/07/11 Due: 12/07/12

A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00539721 Org: User:
Start: 10/31/07 End: 07/31/08 Due: 07/31/09

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

Phase: N/A Priority: Normal
NCT ID: NCT00894530 Org: User:
Start: 05/31/09 End: 12/31/09 Due: 12/31/10

A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)

Phase: N/A Priority: Normal
NCT ID: NCT02532868 Org: User:
Start: 05/31/05 End: 01/31/08 Due: 01/31/09